Leerink Partnrs Issues Positive Estimate for AUPH Earnings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research note issued on Thursday, November 7th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will earn $0.10 per share for the quarter, up from their prior forecast of $0.05. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.13 per share.

AUPH has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. Finally, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Down 1.3 %

Shares of Aurinia Pharmaceuticals stock opened at $8.38 on Monday. The stock has a market capitalization of $1.20 billion, a P/E ratio of -55.86 and a beta of 1.45. Aurinia Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $10.05. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33. The stock’s 50-day simple moving average is $7.16 and its 200 day simple moving average is $6.15.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Aurinia Pharmaceuticals by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after buying an additional 89,940 shares during the last quarter. Intech Investment Management LLC bought a new stake in Aurinia Pharmaceuticals in the third quarter valued at $262,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at about $3,330,000. Segall Bryant & Hamill LLC lifted its stake in shares of Aurinia Pharmaceuticals by 1.6% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after purchasing an additional 9,031 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Aurinia Pharmaceuticals by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 10,700 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Insiders Place Their Bets

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the transaction, the director now directly owns 13,356 shares in the company, valued at $112,591.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.